Plasma Protein Analysis Identifies New Drug Targets for Atopic Dermatitis

A recent study investigated how plasma proteins can serve as biomarkers for atopic dermatitis (AD), offering insights that may lead to more personalized and targeted therapies for the condition. The study was published in Scientific Reports.¹

Image Credit: © triocean - stock.adobe.com

Background and Methods

Researchers have increasingly turned to plasma proteomics to explore how specific plasma proteins correlate with disease severity and treatment response in AD.² Plasma protein profiling provides a comprehensive overview of potential biomarkers that could guide more effective, individualized treatment strategies.

The present study aimed to identify plasma proteins that are differentially expressed in patients with AD and how these protein profiles relate to disease severity, treatment outcomes, and other clinical variables.

A cohort of patients with varying stages of AD was recruited for the study. Plasma samples were collected from both active flare-up and remission phases, and mass spectrometry was used to identify and quantify proteins in the plasma. Data were analyzed to identify potential biomarkers for disease progression and therapeutic targets. The researchers also examined how these proteins related to clinical parameters, such as the Severity Scoring of Atopic Dermatitis (SCORAD) index, and previous treatment responses.

Findings

The proteomic analysis revealed several plasma proteins that were significantly altered in patients with active AD compared to healthy controls. Notably, proteins associated with immune regulation, inflammation, and skin barrier function were found to be upregulated in AD patients during flare-ups. One key protein identified was calgranulin A, which showed a strong correlation with disease severity, particularly in patients with more severe flare-ups.

Additionally, serum amyloid A, a protein involved in the acute-phase response, was found to be elevated in the plasma of patients with AD, with higher levels correlating with worse SCORAD scores.

The study also uncovered a potential link between C-C motif chemokine ligand 5 and AD severity, suggesting that this chemokine could serve as a target for future therapeutic interventions. Furthermore, the researchers observed that proteins related to the skin barrier, such as filaggrin, were found in reduced concentrations in the plasma of patients with AD, supporting the notion that disruptions in barrier function play a significant role in the pathogenesis of the disease.

Furthermore, plasma protein profiles were able to distinguish between patients who had a positive response to treatment and those who did not, with specific proteins such as peroxiredoxin 6 showing promise as predictive markers for treatment efficacy. This finding suggests that plasma proteomics could be used to guide treatment decisions.

Conclusions

The study may have been limited by a relatively small sample size, which may limit the generalizability of the findings. The study also focused on a specific cohort of AD patients, and the plasma protein profiles identified may not be universally applicable across all populations with the condition.

According to study authors Luo et al, future research should involve larger, more diverse patient populations to validate these findings and explore the potential of plasma protein biomarkers in clinical practice. Additionally, further investigation is needed into how these proteins could be targeted with novel therapeutics to improve patient outcomes.

Overall, the findings suggest that plasma proteomics holds significant promise for advancing the understanding of AD and improving patient care through personalized treatment strategies.

References

1. Luo C, Zhang Y, Feng Q, et al. Novel candidate plasma proteins for the pathogenesis and treatment of atopic dermatitis revealed by proteome-wide association study. Sci Rep. 14, 30096 (2024). https://doi.org/10.1038/s41598-024-79906-x
2. Cao Z, Li Q, Li Y, et al. Identification of plasma protein markers of allergic disease risk: a mendelian randomization approach to proteomic analysis. BMC Genomics. 25, 503 (2024). https://doi.org/10.1186/s12864-024-10412-0